CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
Upfront consideration includes 616,698 shares of CNS common stock; future milestone payments up to $100M in cash or shares, plus royalties of 3.0%-7.5%.
TPI 287 showed 60% objective response rate and 13.4 months overall survival in a Phase 1 trial with bevacizumab in recurrent GBM.
Company plans to engage FDA in 2025 for a potential registration study of TPI 287 in recurrent glioblastoma.
Topline results from Berubicin pivotal trial expected in first half of 2025; TPI 287 will leverage existing clinical infrastructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.